fashion -WSS

fashion

author：hotspot 2025-09-29 22:48:22 - browse：6636

KalVista Pharmaceuticals said Tuesday that its oral, on-demand treatment for the swelling “attacks” commonly experienced by patients with a genetic condition called hereditary angioedema achieved the goals of a Phase 3 clinical trial.

Based on the study results, the company plans to submit a marketing application to the Food and Drug Administration by the middle of the year. Regulatory filings in Europe and Japan will be completed later in the year.

In the Phase 3 study involving 136 participants, a low and high dose of Kalvista’s drug, called sebetralstat, showed a median time to the beginning of symptom relief of 1.6 hours and 1.8 hours, respectively, compared to 6.7 hours for a placebo. The result was statistically significant and achieved the study’s main efficacy goal.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Medical student insurance fails on mental health care coverage

hotspot

WSS

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

Biotech stock slump in 2023: awaiting the turnaround

Brain injuries and the importance of a second opinion

How to convince healthy people to buy insurance

Thermo Fisher plant for manufacturing gene therapies to expand

focus

fashion

hotspot

As demand for Covid shots wanes, Moderna seeks its next success

CDC's new outbreak response network to include Northeastern

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Thermo Fisher plant for manufacturing gene therapies to expand

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Second xenotransplant done with gene

Duchenne breakthrough therapy leaves behind pioneering families

Experts study whether long Covid risk adds up with each reinfection

Psychedelics group wrestles with new pharma identity

Bill would allow buprenorphine prescription for addiction via telehealth

focus

What is microchimerism and how does it affect maternal health?

Prime Medicine says its gene editing passes test in monkeys

Explaining an after

Lasker Awards 2023: Winners in biomedical research

Changes to biosimilar regulatory framework must prioritize patients

Life sciences investors close nearly $6 billion in new funds

Wikipedia

hotspot

hotspot

hotspot